I think this is exactly correct, although in addition to making it easier for shorts, stock price is mainly an result of supply and demand; limited ability for institutional investors as a source of potential buyers is an enormous limit on demand, price, and price stability for CYDY stock. For comparison:

Institutional ownership CYDY: 0.11%, 21 institutions
Institutional ownership GILD: 80.07%, 2149 Institutions
Bristol-Myers: 76%, 2819 institutions
Pfizer: 70%, 3161 institutions

EUA/Approval (along with the positive capital milestone and perhaps reconstitution of BoD) will enable uplist; uplist will enable increased institutional ownership, which will significantly increase demand for the stock and big/smart money investment. Imagine if institutional ownership increased to roughly same percent as other pharma - share price will follow.

Quote:

---

In my opinion , the downward drift more than up days is the amount of Retail buyers in this stock . It’s the OTC curse. Most large investment firms cannot invest in OTC and others can’t invest in “penny” stocks under 5 bucks a share. So we have limited buyer power and a helluva lot of short activity. It’s why shorts love OTC. Easy Pickens

Read More: https://investorshangout.com/post/view?id=607...z6oAfl5b4O

---